Actively Recruiting
Study of Deucravacitinib Treatment Effects on Immune Cells in Adults with Moderate to Severe Psoriasis
Led by University of California, San Francisco · Updated on 2026-06-04
25
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating how deucravacitinib, a Tyrosine kinase 2 TYK2 blocker, affects immune cells in patients with moderate to severe psoriasis vulgaris. This Phase 4, open-label study involves 25 participants and aims to understand the changes in skin and blood immune cell function before and after treatment. Participants will receive deucravacitinib treatment for six months. During this time, skin biopsies and blood samples will be collected before starting treatment and during the treatment period. These samples will undergo molecular profiling to assess how deucravacitinib changes psoriatic T cell signatures. Throughout the study, participants will be monitored through biopsies, blood analysis, and clinical assessments including the Psoriasis Area and Severity Index PASI score, measured at baseline and after four months. The study focuses on safety and immune response changes during the six-month treatment period. Total participation time corresponds with the treatment duration and associated assessments.
CONDITIONS
Brief Title
Correction of Psoriatic T Cell Signatures by Deucravacitinib
Research Team
R
Raymond Cho, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
